ALIM News and Press, Alimera Sciences Inc. From 01/09/23

ATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced t...

ATLANTA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced t...

ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces f...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although it’s not a topic that everyone loves to hear, the concept of stocks to sell is a necessary one. Fundamentally, with fears of a global recession rising , investors need to start preparing for the worst. Of c...

Alimera Sciences, Inc. (ALIM) Q3 2022 Results Conference Call November 14, 2022 09:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference ...

Alimera Sciences press release ( NASDAQ: ALIM ): Q3 GAAP EPS of -$0.75 misses by $0.35 . Revenue of $13.6M (+11.9% Y/Y) misses by $1.45M . On September 30, 2022, Alimera had cash and cash equivalents of approximately $5.5 million dollars, compared to $7.9 ...

Consolidated Net Product Revenue of $13.6 Million, up 11% vs. Third Quarter of 2021 Net Product Revenue Was Unfavorably Impacted by Approximately $800,000 in Foreign Currency Fluctuations Excluding Fluctuations in Foreign Currency Exchange Rates, Consolidat...

Alimera Sciences ( NASDAQ: ALIM ) is scheduled to announce Q3 earnings results on Monday, November 14th, before market open. The consensus EPS Estimate is -$0.37 and the consensus Revenue Estimate is $15.05M (+23.9% Y/Y). For further details see: Alimera Sciences...

ATLANTA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will...

ATLANTA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announc...